GILD News Alert Gilead Sciences (GILD) 105.96 09/19/2014 17:

New Post Public Reply Private Reply Replies (0) Message Board

Sep 19, 2014 at 6:03 PM

Gilead Sciences (GILD) 105.96 $GILD

Spectrum Pharmaceuticals Out-Licenses Products in China - Analyst Blog
Zacks Equity Research - Zacks Investment Research - 48 mins ago
Spectrum Pharmaceuticals (SPPI) announced that it has out-licensed two approved products and a candidate to CASI Pharmaceuticals.

Bayer to Shed MaterialScience Business, Shares Rise - Analyst Blog
Zacks Equity Research - Zacks Investment Research - 53 mins ago
Bayer (BAYRY) announced its intention to shed its MaterialScience business and focus fully on its HealthCare and CropScience segments.

Eli Lilly's Trulicity Approved by FDA for Type II Diabetes - Analyst Blog
Zacks Equity Research - Zacks Investment Research - 1 hr 13 mins ago
Eli Lilly and Company (LLY) received good news when the FDA approved its new injectable diabetes treatment, Trulicity, for adults suffering from type II diabetes.

Is Merck KGaA on Track with its "Fit for 2018" Program? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 19, 1:50PM CDT
Merck KGaA (MKGAF) remains on track for its "Fit for 2018" program and discusses its plans regarding the immunology, oncology and immuno-oncology pipeline.

Midday Glance: Biotechnology companies
AP - Fri Sep 19, 12:33PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:

Dividend Aristocrats: Time to Buy AbbVie Inc Stock?
George Budwell, The Motley Fool - Motley Fool - Fri Sep 19, 11:32AM CDT
Dividend stocks are a powerful force within a well-balanced portfolio because they can dramatically increase the rate of compounding interest through dividend reinvestment plans. Not all dividend stocks are great investment vehicles, however. For...

Gilead's Zydelig Approved In EU; Imbruvica In Wings
at Investor's Business Daily - Fri Sep 19, 11:17AM CDT
The European Commission (EC) approved Gilead Sciences' (GILD) drug Zydelig for two blood cancers on Friday, sending Gilead stock up as much as 1.9%, though shares were flat in midday trading in the stock market today. The EC approved the drug for...

5 Things Gilead Sciences, Inc. Management Wants You to Know
Brian Orelli, The Motley Fool - Motley Fool - Fri Sep 19, 10:30AM CDT
Gilead Sciences presented at the Morgan Stanley Healthcare Conference last week. Rather than the standard presentation of a slide deck, the conference is more of a Q&A, which produces off-the-cuff responses that can be more enlightening for...

Early Glance: Biotechnology companies
AP - Fri Sep 19, 9:16AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are up at 10 a.m.:

Stock Market News for September 19, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Fri Sep 19, 9:10AM CDT
Benchmarks settled in the green on Thursday a day after Fed’s pledge to keep short-term interest rates near zero for a “considerable time”

VIVUS Inc. (VVUS) Rises: Stock Adds 12.4% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Sep 19, 8:32AM CDT
VIVUS Inc. (VVUS) was a big mover last session, as the company saw its shares rise more than 12% on the day.

Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent
PR Newswire - Fri Sep 19, 7:15AM CDT
BioTech News Coverage: Progress made as biotech companies release latest developments, patents and results of studies and trials. Companies in focus are: GenSpera Inc. (OTC: GNSZ), Eli Lilly and Company (NYSE: LLY), Gilead Sciences Inc. (NASDAQ: GILD), Celgene Corporation (NASDAQ: CELG) and Arena Pharmaceuticals Inc. (NASDAQ: ARNA)

European Commission Grants Marketing Authorization for Gilead's Zydelig(R) (Idelalisib) for the Treatment of Chronic Lymphocytic Leukemia and Follicular Lymphoma
Business Wire - Fri Sep 19, 5:23AM CDT
Gilead Sciences, Inc. (Nasdaq:GILD) today announced that the European Commission has granted marketing authorization for Zydelig(R) (idelalisib), 150 mg tablets, a first-in-class oral treatment for two incurable blood cancers - chronic lymphocytic leukemia (CLL) and follicular lymphoma (FL). For the treatment of CLL, Zydelig has been approved for use in combination with rituximab for patients who have received at least one prior therapy; or as first-line treatment in the presence of 17p deletion or TP53 mutation in patients unsuitable for chemo-immunotherapy. For the treatment of FL, Zydelig has been approved as a monotherapy in patients who are refractory to two prior lines of treatment. Zydelig inhibits PI3K delta, a protein that is overexpressed in many B-cell malignancies and plays a role in the viability, proliferation and migration of these cancer cells.

Most active Nasdaq-traded stocks
AP - Thu Sep 18, 5:04PM CDT
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:

Final Glance: Biotechnology companies
AP - Thu Sep 18, 5:04PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were up at the close of trading:

Sanofi & MyoKardia Ink Deal to Develop Cardiomyopathies - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 18, 4:35PM CDT
Sanofi (SNY) announced that it has entered into an agreement with MyoKardia, Inc. to discover and develop targeted therapeutics for cardiomyopathies.

Bayer/Orion Progress with Prostate Cancer Drug ODM-201 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 18, 4:15PM CDT
Bayer (BAYRY) and Orion Corp. announced that they have started enrolling patients for a phase III study on ODM-201.

Alnylam (ALNY) to File Clinical Trial Application for ALN-CC5 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 18, 4:10PM CDT
Alnylam Pharmaceuticals (ALNY) intends to file a clinical trial application for ALN-CC5 by year end.

Gilead Down on Weak Simtuzumab Data and Sovaldi News - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 18, 3:16PM CDT
Shares of Gilead (GILD) were down following a couple of setbacks.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Microplastics Found in Human Blood: Alarming Evidence

An Unsettling Discovery in Our Veins Microplastics in the blood? Yep, you read that right, and it’s not some sci-fi horror story—it’s today’s harsh reality. A riveting report from the likes of the Plastic Pollution Coalition and the Canadian Association of Physicians for the Environment has thrown a bucket of cold water on us. They uncovered microplastics in 96%...

FirstEnergy Funds Boost Housing Stability Across States

FirstEnergy's Commitment to Shelter and Safety You know what gives a warm feeling even in the cold, hard world of finance? Watching a company like FirstEnergy put their money where their mouth is with real action in the community. They're dishing out $125,000 in grants across West Virginia and Maryland, targeting groups that help folks dodging homelessness and domestic...

Lennox Faces Pressures Amidst Strong Revenue Growth

Revenue Surge but Margin Squeeze Out there in the land of HVAC, Lennox International (NYSE: LII) just dropped its third quarter earnings for 2026. Sure, they raked in a solid $1.6 billion—up a hearty 10%. But all that glitters ain't gold, and the company's operating income took a hit down to $312 million, shedding a cool five percent from last year. Challenges Weighing...

New Research Awards Target Drug Resistance in Cancers

Well, this is a breath of fresh air in the lung cancer scene, let's talk about some promising news for those battling RET-positive cancers. The LUNGevity Foundation and RETpositive have handed out some well-deserved awards to researchers aiming to crack the stubborn nut of drug resistance in RET-positive cancer therapies. Changing the Game for RET-positive Cancer RET gene...

Bracco's $230M U.S. Expansion: A Strategic Leap

Bracco's Bold Move into U.S. Manufacturing In the bustling world of diagnostic imaging, Bracco's latest announcement is like a welcome jolt. They're shelling out $230 million for a new manufacturing facility in Sanford, North Carolina. If you've been around the block in this sector, this move screams ambition—Bracco's playing the long game here. Strategic Location: A...

Venezuelan Crude Hits Texas: NABEP's Bold Move

Venezuelan Crude Docking in Texas Signals New Energy Dynamics Batten down the hatches, 'cause NABEP's Venezuelan crude has made a splashy arrival in Texas. We're talking 1 million barrels, folks, the first of its kind under a fresh U.S. deal. This ain't your grandpa's oil shipment from the Middle East that takes forever to get here—nope, this crude made a pit stop in...

HOST's $50M Boost Fuels Avondale's Expansion

Big Bucks for Avondale's Next Leap HOST isn't playing around with pocket change here. The company's coughing up a neat $50 million to propel Avondale Global Gateway into its next chapter. This investment means serious business—it’s cranking up capacity like a power plant on overdrive, laying down more rail, warehouse spaces, and dock improvements. A new...

Kyungtz'e Eosan Sooryukje: Honoring Spirits and History

An Enchanting Ritual Comes to NYC Some things transcend the humdrum of everyday life, and right now, New York's set to witness exactly that. It's not every day you get treated to Korea's deep-rooted Buddhist traditions, but come November 13 and 14, that's precisely what's in store. The Korean Cultural Center New York (KCCNY) is bringing Kyungtz'e Eosan Sooryukje to the...

Strategic Resources Faces Board Shakeup, AGM Announced

A Shift in Strategic Resources' Boardroom Dynamics On days like these, companies aren't just ticking boxes. They're repositioning themselves for a future painted with a whole bunch of ‘what ifs’, and Strategic Resources Inc. is no exception. This isn’t just your run-of-the-mill board shuffle—Michael Moore’s resignation marks a pivot moment. Now, you might ask...

Corgi Insurance Eyes $100B Auto Market with New Launch

Leaping Into a Booming Market Well, it looks like someone lit a fire under Corgi Insurance, and they're ready to chase bigger bones. They’ve just rolled out a product called Corgi Business Auto, signaling quite a bold move into the hefty, nearly $100 billion U.S. commercial auto insurance arena. Now, as an old hand at this game, my ears perk up whenever I see a player...